Michael H. Mulroy
CIK 1509725 · President and CEO · last filed 2026-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$319.7K
Companies
7
Total Filings
47
Lifetime Open-Market Net
-$2.35M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LCTX | Director | 298,555 | $1.07 | $319.5K | $32.4K | 10 | 2026-07-02 |
| Serina Therapeutics, Inc. (AGE) Delisted | Director | — | $11.10 | — | $0 | 1 | 2019-03-13 |
| Asterias Biotherapeutics, Inc. (AST) Delisted | President and CEO | 350,210 | — | — | $54.9K | 13 | 2019-03-05 |
| Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Director | 32,550 | — | — | $0 | 4 | 2018-07-03 |
| Asterias Biotherapeutics, Inc. (AST.WS) Delisted | President and CEO | 1,537 | — | — | $5.0K | 2 | 2017-09-27 |
| QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | See Remarks | 65,714 | — | — | -$2.44M | 11 | 2014-08-13 |
| BTX | Director | 35 | $7.87 | $275 | $0 | 3 | 2013-10-10 |
Recent Filings · Page 4 of 5
47 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-07-05 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-07-06 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-08-18 | — | Disp (D) | −73,259 | $0 | |
| 2014-08-13 | QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | Mixed | −11,349 | -$923.3K | EDGAR |
| 2014-08-04 | QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | Tax (F) | −1,304 | -$120.4K | EDGAR |
| 2014-07-14 | QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | Mixed | — | -$766.5K | EDGAR |
| 2014-03-12 | QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | Mixed | — | -$505.6K | EDGAR |
| 2014-02-26 | QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | Mixed | +11,281 | -$997.4K | EDGAR |
| 2013-10-10 | BTX | Grant (A) | +40,000 | $0 | EDGAR |
| 2013-08-02 | QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | Grant (A) | +10,000 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.